Clinical Trials
13 trialsNCT06064877 2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT03422536 2024-09-04
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Phase 2 Completed
NCT03316599 2021-08-03
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02318368 2020-10-22
FOCAL
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT04100330 2020-03-31
CyFi2
AVEO Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT02109627 2020-03-24
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
University of California, San Francisco
Phase 1 Terminated
NCT02277197 2019-04-18
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Pittsburgh
Phase 1 Completed
NCT02277184 2017-11-13
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT02090127 2015-07-29
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
AVEO Pharmaceuticals, Inc.
No longer available
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00725634 2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00969410 2012-04-12
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT01189513 2012-02-20
SCH-900105 in Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn